Oncology Access Director - US Market Access

Overview

The Oncology Access Director will develop and expand relationships with population health decision makers at priority accounts (including large community practices, select academic medical centers/health systems, and Oncology support organizations/societies) within a given geography. This role is accountable for leading the development of access strategies at priority accounts and within a defined geography to remove clinical, financial, and operational barriers to testing and Stemline products for patients and providers. The Oncology Access Director will serve as lead for Stemline engagement with population health decision makers and collaborate with Stemline internal stakeholders to execute a broader strategic account plan.

Responsibilities

• Serve as lead for Stemline engagement with population health decision makers (PHDMs) at priority accounts
• Develop account plans for priority accounts to ensure optimal access for Stemline products in a competitive and dynamic marketplace
• Identify competitive threats and develop response strategies to ensure optimal access to products
• Partner with external precision medicine personnel within priority accounts to identify and remove barriers to testing (BPDCN and mBC).
• Facilitate cross functional planning for priority accounts, which includes engagement of key personnel involved in formulary/pathway/protocol decision making and ensuring all Stemline resources are used effectively to convey the value of our medicines to the accounts for their patients
• Responsible for priority account alignment across other business units and brand teams to include clear objectives, timelines, and accountability.
• Compliantly engage Medical Affairs resources to support optimal product access across assigned accounts
• Partner across Market Access to understand and pull through contract opportunities (where applicable)
• Manage meeting planning and attendance to maximize the engagement and Stemline branding opportunities
• Work collaboratively with all Stemline strategic partners, including (but not limited to) Market Access, Fields Sales, Medical Affairs, and Marketing.
• Leverage internal resources to identify and support any reimbursement and access issues
• Provide education and services pertaining to access, coverage, coding, reimbursement and affordability solutions for Stemline products, in a compliant and effective manner.

Qualifications

Technical: 

• In-depth knowledge of product prescribing information
• Well-developed negotiation skills.
• A high level of awareness and understanding of the implications and opportunities of contract strategy.
• Deep knowledge of the patient and product journey for both infused and oral oncology products.
• A thorough knowledge of strategic marketing and selling.
• An in-depth knowledge of key account selling for targeted channels/segments.
• A high level of knowledge of current reimbursement modalities, including AWP, WAC, ASP, and MAC pricing.
• A thorough understanding of all corporate policies and procedures.
• Thorough understanding of Patient Support and Services.
• An in-depth knowledge of the marketplace and applies that understanding to targeted account segment marketing, distribution strategy development and implementation to accomplish business objectives.
• The ability to influence key decision makers in targeted account segments.

Planning and Analysis: 

• Plan, organize, and analyze in order to accomplish company and individual sales and business objectives.
• Maintain ability to develop, plan specific activities, implement, monitor, and adjust all-inclusive pull through plans that involve sales and sales leadership.
• Develop and update strategic account plans for priority accounts
• Manage expenses within set budgetary guidelines.
• Manage all assigned accounts through proper use of travel and administrative time.

Communication: 

• Demonstrated ability to effectively communicate and collaborate cross functionally
• Facilitate internal strategic account team meetings to align on common goals
• Strong oral, written, and group communication skills with both internal and external customers.
• Effective communication with targeted accounts including C-suite customers.
• In a timely and accurate manner, submit all budgetary information, expense reports and administrative reports as requested. 

Required: 

• 10+ years of proven success in biotech/pharmaceutical industry or related healthcare field. 
• Minimum of 5 years’ combined experience in market access customer facing role and/or sales leadership
• Significant experience and knowledge of the community oncology and health system segments including established relationships with key decision makers
• Advanced knowledge of reimbursement and access related to provider administered (buy/bill) and oral Oncology products including influence of pathways, payer coverage, reimbursement policies and processes, and patient services.
• Oncology market access launch experience of new products/start-up experience a plus
• Demonstrated ability to collaborate with a diverse matrix of internal stakeholders (e.g., Market Access Account team, Corporate Accounts, field sales, brand marketing, Medical, legal, compliance, Trade, Patient Services, Data & Analytics) to achieve access goals.
• Ability to identify future policies, practices and trends that will affect community oncology practice management and access decision making in the marketplace
• Demonstrated ability to effectively influence without authority.
• Excellent communication, presentation and negotiation skills required
• Field Based: Willingness to travel up to 50 percent of time, including some weekend availability for meetings

Base Salary Range of $230,000 - $265,000 plus annual bonus and Long-Term Incentives.  Menarini Stemline offers generous compensation and benefits packages, including Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees.  All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.